Gilead agrees 127-country remdesivir licence with generic makers
14-05-2020
Gilead secures new anti-cancer therapy in $4.9bn deal
02-03-2020
Sundry Photography / Shutterstock.com
Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, Tizona, US Food and Drug Administration, FDA, Daniel O’Day, TTX-080, cancer, immuno-oncology
